Xencor (XNCR) News Today $10.51 -0.33 (-3.04%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$10.52 +0.01 (+0.05%) As of 04/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Barclays PLC Boosts Stock Position in Xencor, Inc. (NASDAQ:XNCR)Barclays PLC increased its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 112.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 330,745 shares of the biopharmaceutical company's stock after buying an additionApril 26 at 4:07 AM | marketbeat.comWilliam Blair Predicts Xencor's Q1 Earnings (NASDAQ:XNCR)Xencor, Inc. (NASDAQ:XNCR - Free Report) - Analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Xencor in a research note issued to investors on Monday, April 21st. William Blair analyst M. Phipps anticipates that the biopharmaceutical company will earn ($0.84April 25 at 6:30 AM | marketbeat.comInvesco Ltd. Sells 156,130 Shares of Xencor, Inc. (NASDAQ:XNCR)Invesco Ltd. reduced its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 25.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 454,745 shares of the biopharmaceutical company's stock after selling 156,130 shares during the peApril 25 at 3:33 AM | marketbeat.comXencor (NASDAQ:XNCR) Shares Down 2.7% - Here's WhyXencor (NASDAQ:XNCR) Stock Price Down 2.7% - Time to Sell?April 24 at 1:09 PM | marketbeat.comQ1 Earnings Estimate for Xencor Issued By William BlairApril 24 at 1:20 AM | americanbankingnews.comXencor (NASDAQ:XNCR) Stock Price Up 9.3% - Here's What HappenedXencor (NASDAQ:XNCR) Shares Up 9.3% - Time to Buy?April 23 at 1:24 PM | marketbeat.comXencor (NASDAQ:XNCR) Now Covered by William BlairWilliam Blair initiated coverage on Xencor in a research note on Monday. They issued an "outperform" rating on the stock.April 23 at 9:20 AM | marketbeat.comWilliam Blair starts Xencor stock with Outperform ratingApril 23 at 4:15 AM | uk.investing.comWilliam Blair Initiates Coverage of Xencor (XNCR) with Outperform RecommendationApril 22, 2025 | msn.comBrokerages Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $33.86April 22, 2025 | americanbankingnews.comWilliam Blair Begins Coverage on Xencor (NASDAQ:XNCR)April 22, 2025 | americanbankingnews.comXencor initiated with an Outperform at William BlairApril 21, 2025 | markets.businessinsider.comXencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Buy" by AnalystsXencor, Inc. (NASDAQ:XNCR - Get Free Report) has been given a consensus rating of "Buy" by the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the companApril 20, 2025 | marketbeat.comXencor participates in a conference call with JPMorganApril 19, 2025 | markets.businessinsider.comXencor (NASDAQ:XNCR) Stock Price Up 4.9% - What's Next?Xencor (NASDAQ:XNCR) Trading Up 4.9% - Here's What HappenedApril 17, 2025 | marketbeat.comGeode Capital Management LLC Acquires 179,526 Shares of Xencor, Inc. (NASDAQ:XNCR)Geode Capital Management LLC increased its stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 12.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,634,876 shares of the biopharmaceutical company's stocApril 17, 2025 | marketbeat.comNorges Bank Buys New Position in Xencor, Inc. (NASDAQ:XNCR)Norges Bank purchased a new position in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 147,823 shares of the biopharmaceutical company's stock, valued at approximately $3,397,April 13, 2025 | marketbeat.comXencor, Inc.: No Major Near Term CatalystsApril 11, 2025 | seekingalpha.comXencor, Inc. (NASDAQ:XNCR) Shares Sold by Trexquant Investment LPTrexquant Investment LP cut its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 59.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 83,241 shares of the biopharmaceutical company's stock afApril 11, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Shares Down 5.4% - What's Next?Xencor (NASDAQ:XNCR) Stock Price Down 5.4% - What's Next?April 10, 2025 | marketbeat.comXencor’s SWOT analysis: biotech stock faces pivotal year aheadApril 10, 2025 | uk.investing.comXencor (NASDAQ:XNCR) Reaches New 52-Week Low - What's Next?Xencor (NASDAQ:XNCR) Sets New 52-Week Low - Should You Sell?April 9, 2025 | marketbeat.comADAR1 Capital Management LLC Sells 107,655 Shares of Xencor, Inc. (NASDAQ:XNCR)ADAR1 Capital Management LLC decreased its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 31.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 234,607 shares of the biopharmaceuticaApril 9, 2025 | marketbeat.comFinepoint Capital LP Purchases Shares of 660,000 Xencor, Inc. (NASDAQ:XNCR)Finepoint Capital LP acquired a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 660,000 shares of the biopharmaceutical company's stock, valued at approximatelApril 8, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 5.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,017,366 shares of the biopharmaceutical company's sApril 8, 2025 | marketbeat.comBarclays Keeps Their Sell Rating on Xencor (XNCR)April 3, 2025 | markets.businessinsider.comXencor (NASDAQ:XNCR) Trading Down 7.4% - Here's What HappenedXencor (NASDAQ:XNCR) Trading Down 7.4% - Should You Sell?April 3, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Sets New 52-Week Low - Should You Sell?Xencor (NASDAQ:XNCR) Hits New 12-Month Low - Time to Sell?April 1, 2025 | marketbeat.comRaymond James Financial Inc. Acquires New Holdings in Xencor, Inc. (NASDAQ:XNCR)Raymond James Financial Inc. bought a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 101,346 shares of the biopharmaceutical company's stock, valued at approxMarch 30, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Shares Acquired by Loomis Sayles & Co. L PLoomis Sayles & Co. L P increased its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 21.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,092,346 shares of the biopharmaceutical company's stock after buying an additMarch 29, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Stock Price Down 5.3% - Here's WhyXencor (NASDAQ:XNCR) Trading Down 5.3% - Should You Sell?March 27, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Hits New 12-Month Low - Here's What HappenedXencor (NASDAQ:XNCR) Reaches New 1-Year Low - Should You Sell?March 26, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Buy" from BrokeragesXencor, Inc. (NASDAQ:XNCR - Get Free Report) has received a consensus rating of "Buy" from the eight ratings firms that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the companyMarch 25, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Trading 3.9% Higher - Here's WhyXencor (NASDAQ:XNCR) Trading Up 3.9% - What's Next?March 21, 2025 | marketbeat.comAmundi Acquires 24,494 Shares of Xencor, Inc. (NASDAQ:XNCR)Amundi increased its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 225.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,380 shares of the biopharmaceutical company's stock afteMarch 20, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Reaches New 12-Month Low - What's Next?Xencor (NASDAQ:XNCR) Sets New 52-Week Low - Here's What HappenedMarch 18, 2025 | marketbeat.comPrimecap Management Co. CA Decreases Stock Holdings in Xencor, Inc. (NASDAQ:XNCR)Primecap Management Co. CA trimmed its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 1.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,984,432 shares of the biopharmaceuticaMarch 18, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Stock Rating Lowered by StockNews.comStockNews.com cut shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday.March 14, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Sets New 52-Week Low - Here's What HappenedXencor (NASDAQ:XNCR) Hits New 1-Year Low - Should You Sell?March 11, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Upgraded by StockNews.com to "Hold" RatingStockNews.com upgraded shares of Xencor from a "sell" rating to a "hold" rating in a report on Thursday.March 6, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Sets New 1-Year Low - Here's WhyXencor (NASDAQ:XNCR) Hits New 12-Month Low - What's Next?March 5, 2025 | marketbeat.comPrincipal Financial Group Inc. Grows Stock Holdings in Xencor, Inc. (NASDAQ:XNCR)Principal Financial Group Inc. grew its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 16.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 340,145 shares of the biopharmaceutical companyMarch 2, 2025 | marketbeat.comBarclays Reaffirms Their Sell Rating on Xencor (XNCR)March 1, 2025 | markets.businessinsider.comWells Fargo & Company Cuts Xencor (NASDAQ:XNCR) Price Target to $33.00Wells Fargo & Company reduced their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday.March 1, 2025 | marketbeat.comXencor price target lowered to $32 from $34 at RBC CapitalMarch 1, 2025 | markets.businessinsider.comXencor, Inc. (NASDAQ:XNCR) Stake Raised by Rhumbline AdvisersRhumbline Advisers increased its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 11.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 170,000 shares of the bioMarch 1, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Posts Quarterly Earnings ResultsXencor (NASDAQ:XNCR - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%.February 28, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Trading 7.8% Higher on Better-Than-Expected EarningsXencor (NASDAQ:XNCR) Stock Price Up 7.8% Following Earnings BeatFebruary 28, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (IOVA), Xencor (XNCR) and Merus (MRUS)February 28, 2025 | markets.businessinsider.comXencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight research firms that are currently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned aFebruary 28, 2025 | marketbeat.com Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address XNCR Media Mentions By Week XNCR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XNCR News Sentiment▼0.781.03▲Average Medical News Sentiment XNCR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XNCR Articles This Week▼184▲XNCR Articles Average Week Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Merus News MorphoSys News Scholar Rock News Protagonist Therapeutics News Crinetics Pharmaceuticals News SpringWorks Therapeutics News Organon & Co. News Catalyst Pharmaceuticals News Viking Therapeutics News Xenon Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XNCR) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XNCR Stock Free XNCR Stock Alerts